Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 7Gastrointestinal 2Other neoplasm 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 57Carcinoma, Renal Cell 18Urinary Bladder Neoplasms 13Neoplasm Metastasis 8Sarcoma 7Ovarian Neoplasms 6Melanoma 6Glioma 6Breast Neoplasms 6Wilms Tumor 5Uterine Cervical Neoplasms 5Pancreatic Neoplasms 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Lymphoma, Non-Hodgkin 5Kidney Neoplasms 5Carcinoma, Transitional Cell 5Rhabdoid Tumor 4Neoplasms 4Medulloblastoma 4Lung Neoplasms 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4Ependymoma 4Colorectal Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urethral Neoplasms 3Ureteral Neoplasms 3

Interventions

pembrolizumab 16Nivolumab 9atezolizumab 7Docetaxel 7Cyclophosphamide 5durvalumab 4Ipilimumab 4Gemcitabine 4avelumab 3Specimen Handling 3Radiotherapy 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3temsirolimus 2spartalizumab 2sargramostim 2fludarabine 2epacadostat 2enzalutamide 2cabozantinib 2aldesleukin 2abiraterone 2Therapeutics 2Standard of Care 2Radiosurgery 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Biopsy × Genitourinary × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡